Emerging pathogens in cystic fibrosis: ten years of follow-up in a cohort of patients

被引:66
作者
Spicuzza, L. [1 ]
Sciuto, C. [1 ]
Vitaliti, G. [1 ]
Di Dio, G. [1 ]
Leonardi, S. [1 ]
La Rosa, M. [1 ]
机构
[1] UO Broncopneumol, Dipartimento Pediat, I-95123 Catania, Italy
关键词
STENOTROPHOMONAS-MALTOPHILIA; INFECTION; MICROBIOLOGY; PREVALENCE; EMERGENCE;
D O I
10.1007/s10096-008-0605-4
中图分类号
R51 [传染病];
学科分类号
100201 [内科学];
摘要
In patients with cystic fibrosis (CF), there is an increasing incidence of some uncommon respiratory pathogens, such as Burkholderia cepacia complex (Bcc), Stenotrophomonas maltophilia, and Achromobacter xylosoxidans. In order to evaluate the prevalence and the clinical impact of these pathogens, we retrospectively studied a total of 109 patients followed in our center from 1996 to 2006 and reviewed the results of 1,550 sputum samples. The isolation of Pseudomonas aeruginosa slightly decreased over the observed decade, whereas Staphylococcus aureus exhibited an irregular trend. Infection with Bcc reached a peak in 1998 and successively decreased to a stable 4%. S. maltophilia and A. xylosoxidans were the real emerging pathogens, since first isolation occurred in 2004; however, the percentage of infected patients remained low (7% and 3.2%, respectively) through the years. In conclusion, in our center for CF, the reduced prevalence of P. aeruginosa over the last decade has been associated with a concurrent reduction of infections by Bcc and, as compared to other centers in Italy, Europe, and the US, with a low incidence of emerging pathogens such as S. maltophilia and A. xylosoxidans.
引用
收藏
页码:191 / 195
页数:5
相关论文
共 16 条
[1]
Burkholderia cepacia complex infection in Italian patients with cystic fibrosis:: Prevalence, epidemiology, and genomovar status [J].
Agodi, A ;
Mahenthiralingam, E ;
Barchitta, M ;
Gianninò, V ;
Sciacca, A ;
Stefani, S .
JOURNAL OF CLINICAL MICROBIOLOGY, 2001, 39 (08) :2891-2896
[2]
Microbiology of sputum from patients at cystic fibrosis centers in the United States [J].
Burns, JL ;
Emerson, J ;
Stapp, JR ;
Yim, DL ;
Krzewinski, J ;
Louden, L ;
Ramsey, BW ;
Clausen, CR .
CLINICAL INFECTIOUS DISEASES, 1998, 27 (01) :158-163
[3]
Campana Silvia, 2004, J Cyst Fibros, V3, P159, DOI 10.1016/j.jcf.2004.03.010
[4]
*CFF, 2006, PATIENT REGISTRY ANN
[5]
Demko CA, 1998, PEDIATR PULM, V25, P304, DOI 10.1002/(SICI)1099-0496(199805)25:5<304::AID-PPUL3>3.3.CO
[6]
2-K
[7]
Pathophysiology and management of pulmonary infections in cystic fibrosis [J].
Gibson, RL ;
Burns, JL ;
Ramsey, BW .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2003, 168 (08) :918-951
[8]
Factors affecting the incidence Stenotrophomonas maltophilia isolation in cystic fibrosis [J].
Graff, GR ;
Burns, JL .
CHEST, 2002, 121 (06) :1754-1760
[9]
Chronic infection with Achromobacter xylosoxidans in cystic fibrosis patients;: a retrospective case control study [J].
Hansen, Christine Ronne ;
Pressler, Tacjana ;
Hoiby, Niels ;
Gormsen, Magdalena .
JOURNAL OF CYSTIC FIBROSIS, 2006, 5 (04) :245-251
[10]
Burkholderia cenocepacia and Burkholderia multivorans:: influence on survival in cystic fibrosis [J].
Jones, AM ;
Dodd, ME ;
Govan, JRW ;
Barcus, V ;
Doherty, CJ ;
Morris, J ;
Webb, AK .
THORAX, 2004, 59 (11) :948-951